Novo Nordisk, the Danish drugmaker behind the popular obesity drug Wegovy, warns of fierce competition and market pressures, potentially leading to layoffs. As compounders produce cheaper copycats, U.

Novo Nordisk stock slumped Wednesday after saying it expects compounded versions to undercut sales of its obesity drug, ...

Copenhagen: Danish pharmaceutical giant Novo Nordisk posted a sharp rise in second quarter net profit Wednesday, but rising ...

CNBC's Karen Gilchrist discusses Wegovy-maker Novo Nordisk's efforts to regain U.S. market share amid increased competition ...

Even though Novo Nordisk warned that copycat versions of its obesity and diabetes drugs would hurt sales in the U.S., second-quarter sales saw a 67% rise year on year. More news covers telehealth ...